Navigating Trump 2.0

BioCentury In Depth

The Trump administration and Congress are moving quickly to disrupt the federal government. Biopharma leaders need inside information and reliable analyses to navigate the rapidly evolving environment and distinguish between noise and actionable information. BioCentury’s coverage of policy, law and legislation will provide essential tools as events in Washington reshape the global innovation ecosystem.

Sign up now (free) for access to the featured stories below and put BioCentury to work for you.

Featured Analysis

Complimentary access with registration

ArticlePolitics, Policy & LawMar 8, 2025

Makary hints at his agenda

Makary’s path to Senate confirmation could end DOGE’s influence over FDA, usher in conflicts over MAHA policies

ArticleEditor's CommentaryMar 8, 2025

RIP DEI. Now deliver on the meritocracy ideal — a Perspective

The dismantling of DEI will reveal who can achieve the long-sought goal of hiring the best, not just the ones you know

ArticlePolitics, Policy & LawMar 3, 2025

Turmoil at FDA puts rare disease review capacity at risk

Situation is a ‘five-alarm fire,’ an orphan drug reviewer says

More Navigating Trump 2.0 Analysis from BioCentury

Available to BioCentury Subscribers Only